EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells
Abstract
:1. Introduction
2. Results
2.1. Ocr Is Decreased by MM10 in Prostate Cancer Cells
2.2. Mitochondrial Superoxide Production Is Increased after MM10 24 H Exposure in PC-3 but Not in DU-145 Cells
2.3. DU-145 Cells Have Higher Glutathione Levels and Are More Resistant to Oxidative Stress Than PC-3 Cells
2.4. MM10 Alleviates Tumor Hypoxia in the PC-3 Cancer Model
2.5. MM10 as a Potential Radiosentizer?
3. Discussion
4. Materials and Methods
4.1. Reagents
4.2. Cell Lines and Culture
4.3. OCR Measurements by EPR Spectroscopy
4.4. Mitochondrial Superoxide Assessment by EPR Spectroscopy
4.5. Intracellular Reduced and Oxidized Glutathione Quantification
4.6. Tumor Models In Vivo and Treatments
4.7. In Vivo EPR Oximetry
4.8. Tumor Growth-Delay
4.9. Statistics
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Grasso, D.; Zampieri, L.X.; Capeloa, T.; Van de Velde, J.A.; Sonveaux, P. Mitochondria in cancer. Cell Stress. 2020, 4, 114–146. [Google Scholar] [CrossRef] [PubMed]
- Sainero-Alcolado, L.; Liano-Pons, J.; Ruiz-Pérez, M.V.; Arsenian-Henriksson, M. Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ. 2022, 29, 1304–1317. [Google Scholar] [CrossRef] [PubMed]
- Kalyanaraman, B.; Cheng, G.; Hardy, M.; Ouari, O.; Lopez, M.; Joseph, J.; Zielonka, J.; Dwinell, M.B. A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. Redox Biol. 2018, 14, 316–327. [Google Scholar] [CrossRef] [PubMed]
- Kordes, S.; Pollak, M.N.; Zwinderman, A.H.; Mathot, R.A.; Weterman, M.J.; Beeker, A.; Punt, C.J.; Richel, D.J.; Wilmink, J.W. Metformin in patients with advanced pancreatic cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015, 16, 839–847. [Google Scholar] [CrossRef]
- Heckman-Stoddard, B.M.; Gandini, S.; Puntoni, M.; Dunn, B.K.; Decensi, A.; Szabo, E. Repurposing old drugs to chemoprevention: The case of metformin. Semin. Oncol. 2016, 43, 123–133. [Google Scholar] [CrossRef]
- Kalyanaraman, B.; Cheng, G.; Hardy, M.; Ouari, O.; Sikora, A.; Zielonka, J.; Dwinell, M.B. Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies. Cell Biochem. Biophys. 2017, 75, 311–317. [Google Scholar] [CrossRef]
- Wheaton, W.W.; Weinberg, S.E.; Hamanaka, R.B.; Soberanes, S.; Sullivan, L.B.; Anso, E.; Glasauer, A.; Dufour, E.; Mutlu, G.M.; Budigner, G.S.; et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 2014, 3, e02242. [Google Scholar] [CrossRef]
- Foretz, M.; Guigas, B.; Bertrand, L.; Pollak, M.; Viollet, B. Metformin: From Mechanisms of Action to Therapies. Cell Metab. 2014, 20, 953–966. [Google Scholar] [CrossRef]
- Liu, X.; Romero, I.L.; Litchfield, L.M.; Lengyel, E.; Locasale, J.W. Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab. 2016, 24, 728–739. [Google Scholar] [CrossRef]
- Gui, D.Y.; Sullivan, L.B.; Luengo, A.; Hosios, A.M.; Bush, L.N.; Gitego, N.; Davidson, S.M.; Freinkman, E.; Thomas, C.J.; Vander Heiden, M.G. Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. Cell Metab. 2016, 24, 716–727. [Google Scholar] [CrossRef] [Green Version]
- Kalyanaraman, B.; Cheng, G.; Hardy, M.; Ouari, O.; Sikora, A.; Zielonka, J.; Dwinell, M. Mitochondria-targeted metformins: Anti-tumour and redox signalling mechanisms. Interface Focus 2017, 7, 20160109. [Google Scholar] [CrossRef] [PubMed]
- Cheng, G.; Zielonka, J.; Ouari, O.; Lopez, M.; McAllister, D.; Boyle, K.; Barrios, C.S.; Weber, J.J.; Johnson, B.D.; Hardy, M.; et al. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. Cancer Res. 2016, 76, 3904–3915. [Google Scholar] [PubMed]
- Cheng, G.; Zielonka, J.; Hardy, M.; Ouari, O.; Chitambar, C.R.; Dwinell, M.B.; Kalyanaraman, B. Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators. Oncotarget 2019, 10, 3518–3532. [Google Scholar] [CrossRef] [PubMed]
- Milosevic, M.; Warde, P.; Menard, C.; Chung, P.; Toi, A.; Ishkanian, A.; McLean, M.; Pintilie, M.; Sykes, J.; Gospodarowicz, M.; et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin. Cancer Res. 2012, 18, 2108–2114. [Google Scholar] [CrossRef]
- Fraga, A.; Ribeiro, R.; Principe, P.; Lopes, C.; Medeiros, R. Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings. Clin. Genitourin. Cancer 2015, 13, 295–301. [Google Scholar] [CrossRef]
- Yang, L.; Roberts, D.; Takhar, M.; Erho, N.; Bibby, B.A.S.; Thiruthaneeswaran, N.; Bhandari, V.; Cheng, W.C.; Haider, S.; McCorry, A.M.B.; et al. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine 2018, 31, 182–189. [Google Scholar] [CrossRef]
- Bibby, B.A.S.; Thiruthaneeswaran, N.; Yang, L.; Pereira, R.R.; More, E.; McArt, D.G.; O’Reilly, P.; Bristow, R.G.; Williams, K.J.; Choudhury, A.; et al. Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. BMC Urol. 2021, 21, 96. [Google Scholar] [CrossRef]
- Secomb, T.W.; Hsu, R.; Ong, E.T.; Gross, J.F.; Dewhirst, M.W. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. 1995, 34, 313–316. [Google Scholar] [CrossRef]
- Gallez, B.; Neveu, M.A.; Danhier, P.; Jordan, B.F. Manipulation of tumor oxygenation and radiosensitivity through modification of cell respiration. A critical review of approaches and imaging biomarkers for therapeutic guidance. Biochim. Biophys. Acta Bioenerg. 2017, 1858, 700–711. [Google Scholar] [CrossRef]
- Zannella, V.E.; Dal Pra, A.; Muaddi, H.; McKee, T.D.; Stapleton, S.; Sykes, J.; Glicksman, R.; Chaib, S.; Zamiara, P.; Milosevic, M.; et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin. Cancer Res. 2013, 19, 6741–6750. [Google Scholar] [CrossRef] [Green Version]
- De Bruycker, S.; Vangestel, C.; Van den Wyngaert, T.; Pauwels, P.; Wyffels, L.; Staelens, S.; Stroobants, S. 18F-Flortanidazole Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and Radiotherapy. J. Nucl. Med. 2019, 60, 34–40. [Google Scholar] [CrossRef] [PubMed]
- De Bruycker, S.; Vangestel, C.; Staelens, S.; Wyffels, L.; Detrez, J.; Verschuuren, M.; De Vos, W.H.; Pauwels, P.; Van den Wyngaert, T.; Stroobants, S. Effects of metformin on tumor hypoxia and radiotherapy efficacy: A [18F]HX4 PET imaging study in colorectal cancer xenografts. EJNMMI Res. 2019, 9, 74. [Google Scholar] [CrossRef] [PubMed]
- Jordan, B.F.; Gregoire, V.; Demeure, R.J.; Sonveaux, P.; Feron, O.; O’Hara, J.; Vanhulle, V.P.; Delzenne, N.; Gallez, B. Insulin increases the sensitivity of tumors to irradiation: Involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res. 2002, 62, 3555–3561. [Google Scholar] [PubMed]
- Diepart, C.; Verrax, J.; Calderon, P.B.; Feron, O.; Jordan, B.F.; Gallez, B. Comparison of methods for measuring oxygen consumption in tumor cells in vitro. Anal. Biochem. 2010, 396, 250–256. [Google Scholar] [CrossRef] [PubMed]
- Danhier, P.; Copetti, T.; De Preter, G.; Leveque, P.; Feron, O.; Jordan, B.F.; Sonveaux, P.; Gallez, B. Influence of cell detachment on the respiration rate of tumor and endothelial cells. PLoS ONE 2013, 8, e53324. [Google Scholar]
- Dikalov, S.I.; Kirilyuk, I.; Voynov, M.; Grigor’Ev, I. EPR detection of cellular and mitochondrial superoxide using cyclic hydroxylamines. Free Radic. Res. 2010, 45, 417–430. [Google Scholar] [CrossRef]
- Dikalov, S.I.; Harrison, D.G. Methods for Detection of Mitochondrial and Cellular Reactive Oxygen Species. Antioxid. Redox Signal. 2014, 20, 372–382. [Google Scholar] [CrossRef]
- Scheinok, S.; Capeloa, T.; Porporato, P.E.; Sonveaux, P.; Gallez, B. An EPR Study Using Cyclic Hydroxylamines to Assess the Level of Mitochondrial ROS in Superinvasive Cancer Cells. Cell Biochem. Biophys. 2020, 78, 249–254. [Google Scholar] [CrossRef]
- Swartz, H.M.; Boyer, S.; Gast, P.; Glockner, J.F.; Hu, H.; Liu, K.J.; Moussavi, M.; Norby, S.W.; Vahidi, N.; Walczak, T.; et al. Measurements of pertinent concentrations of oxygen in vivo. Magn. Reason. Med. 1991, 20, 333–339. [Google Scholar] [CrossRef]
- Gallez, B.; Jordan, B.F.; Baudelet, C.; Misson, P.D. Pharmacological modifications of the partial pressure of oxygen in murine tumors: Evaluation using in vivo EPR oximetry. Magn. Reason. Med. 1999, 42, 627–630. [Google Scholar] [CrossRef]
- Gallez, B.; Baudelet, C.; Jordan, B.F. Assessment of tumor oxygenation by electron paramagnetic resonance: Principles and applications. NMR Biomed. 2004, 17, 240–262. [Google Scholar] [CrossRef] [PubMed]
- Jezek, J.; Cooper, K.F.; Strich, R. Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression. Antioxidants 2018, 7, 13. [Google Scholar] [CrossRef] [PubMed]
- Kalyanaraman, B.; Cheng, G.; Hardy, M.; Ouari, O.; Bennett, B.; Zielonka, J. Teaching the basics of reactive oxygen species and their relevance to cancer biology: Mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies. Redox Biol. 2018, 15, 347–362. [Google Scholar] [CrossRef]
- Beckman, J.S.; Minor, R.L., Jr.; White, C.W.; Repine, J.E.; Rosen, G.M.; Freeman, B.A. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. J. Biol. Chem. 1988, 263, 6884–6892. [Google Scholar] [CrossRef]
- Crokart, N.; Jordan, B.F.; Baudelet, C.; Cron, G.O.; Hotton, J.; Radermacher, K.; Gregoire, V.; Beghein, N.; Martinive, P.; Bouzin, C.; et al. Glucocorticoids modulate tumor radiation response through a decrease in tumor oxygen consumption. Clin. Cancer Res. 2007, 13, 630–635. [Google Scholar] [CrossRef] [PubMed]
- Diepart, C.; Karroum, O.; Magat, J.; Feron, O.; Verrax, J.; Calderon, P.B.; Gregoire, V.; Leveque, P.; Stockis, J.; Dauguet, N.; et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res. 2012, 72, 482–490. [Google Scholar] [CrossRef]
- De Preter, G.; Deriemaeker, C.; Danhier, P.; Brisson, L.; Cao Pham, T.T.; Gregoire, V.; Jordan, B.F.; Sonveaux, P.; Gallez, B. A Fast Hydrogen Sulfide-Releasing Donor Increases the Tumor Response to Radiotherapy. Mol. Cancer Ther. 2016, 15, 154–161. [Google Scholar] [CrossRef]
- Gallez, B. The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia. Front. Pharmacol. 2022, 13, 853568. [Google Scholar] [CrossRef]
- Khan, N.; Williams, B.B.; Hou, H.; Li, H.; Swartz, H.M. Repetitive tissue pO2 measurements by electron paramagnetic resonance oximetry: Current status and future potential for experimental and clinical studies. Antioxid. Redox Signal. 2007, 9, 1169–1182. [Google Scholar] [CrossRef]
- Horsman, M.R.; Wouters, B.G.; Joiner, M.C.; Overgaard, J. The oxygen effect and fractionated radiotherapy. In Basic Clinical Radiobiology, 4th ed.; Joiner, M., van der Kogel, A., Eds.; CRC Press: London, UK, 2009; pp. 207–216. [Google Scholar]
- Whillans, D.W.; Hunt, J.W. A rapid-mixing comparison of the mechanisms of radiosensitization by oxygen and misonidazole in CHO cells. Radiat. Res. 1982, 90, 126–141. [Google Scholar] [CrossRef]
- Krishna, M.C.; Matsumoto, S.; Yasui, H.; Saito, K.; Devasahayam, N.; Subramanian, S.; Mitchell, J.B. Electron paramagnetic resonance imaging of tumor pO₂. Radiat. Res. 2012, 177, 376–386. [Google Scholar] [CrossRef] [PubMed]
- Elas, M.; Magwood, J.M.; Butler, B.; Li, C.; Wardak, R.; DeVries, R.; Barth, E.D.; Epel, B.; Rubinstein, S.; Pelizzari, C.A.; et al. EPR oxygen images predict tumor control by a 50% tumor control radiation dose. Cancer Res. 2013, 73, 5328–5335. [Google Scholar] [CrossRef] [PubMed]
- Epel, B.; Halpern, H.J. In Vivo pO2 Imaging of Tumors: Oxymetry with Very Low-Frequency Electron Paramagnetic Resonance. Methods Enzymol. 2015, 564, 501–527. [Google Scholar] [PubMed]
- Epel, B.; Maggio, M.C.; Barth, E.D.; Miller, R.C.; Pelizzari, C.A.; Krzykawska-Serda, M.; Sundramoorthy, S.V.; Aydogan, B.; Weichselbaum, R.R.; Tormyshev, V.M.; et al. Oxygen-Guided Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2019, 103, 977–984. [Google Scholar] [CrossRef] [PubMed]
- Brender, J.R.; Saida, Y.; Devasahayam, N.; Krishna, M.C.; Kishimoto, S. Hypoxia Imaging As a Guide for Hypoxia-Modulated and Hypoxia-Activated Therapy. Antioxid. Redox Signal. 2022, 36, 144–159. [Google Scholar] [CrossRef]
- Swartz, H.M.; Williams, B.B.; Hou, H.; Khan, N.; Jarvis, L.A.; Chen, E.Y.; Schaner, P.E.; Ali, A.; Gallez, B.; Kuppusamy, P.; et al. Direct and Repeated Clinical Measurements of pO2 for Enhancing Cancer Therapy and Other Applications. Adv. Exp. Med. Biol. 2016, 923, 95–104. [Google Scholar]
- Kishimoto, S.; Matsumoto, K.I.; Saito, K.; Enomoto, A.; Matsumoto, S.; Mitchell, J.B.; Devasahayam, N.; Krishna, M.C. Pulsed Electron Paramagnetic Resonance Imaging: Applications in the Studies of Tumor Physiology. Antioxid. Redox Signal. 2018, 28, 1378–1393. [Google Scholar] [CrossRef]
- Kuppusamy, P. Sense and Sensibility of Oxygen in Pathophysiology Using EPR Oximetry. In Measuring Oxidants and Oxidative Stress in Biological Systems; Berliner, L.J., Parinandi, N.L., Eds.; Springer: Cham, Switzerland, 2020; Chapter 9. [Google Scholar]
- Gertsenshteyn, I.; Giurcanu, M.; Vaupel, P.; Halpern, H. Biological validation of electron paramagnetic resonance (EPR) image oxygen thresholds in tissue. J. Physiol. 2021, 599, 1759–1767. [Google Scholar] [CrossRef]
- Gallez, B. Oxygenation Status in Normal Tissues, Pathological Tissues and Malignant Tumors: A pO2 Database Based on Electron Paramagnetic Resonance (EPR) Oximetry Measurements. Appl. Magn. Reason. 2021, 52, 1395–1450. [Google Scholar] [CrossRef]
- d’Hose, D.; Danhier, P.; Northshield, H.; Isenborghs, P.; Jordan, B.F.; Gallez, B. A versatile EPR toolbox for the simultaneous measurement of oxygen consumption and superoxide production. Redox Biol. 2021, 40, 101852. [Google Scholar] [CrossRef]
- d’Hose, D.; Gallez, B. Measurement of Mitochondrial (Dys)Function in Cellular Systems Using Electron Paramagnetic Resonance (EPR): Oxygen Consumption Rate and Superoxide Production. Methods Mol. Biol. 2022, 2497, 83–95. [Google Scholar] [PubMed]
- Baudelet, C.; Gallez, B. Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: Comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes. Magn. Reason. Imaging 2004, 22, 905–912. [Google Scholar] [CrossRef] [PubMed]
- Jordan, B.F.; Baudelet, C.; Gallez, B. Carbon-centered radicals as oxygen sensors for in vivo electron paramagnetic resonance: Screening for an optimal probe among commercially available charcoals. Magn. Reson. Mater. Phys. Biol. Med. 1998, 7, 121–129. [Google Scholar] [CrossRef] [PubMed]
- Walczak, T.; Lesniewski, P.; Salikhov, I.; Sucheta, A.; Szybinski, K.; Swartz, H.M. L-band electron paramagnetic resonance spectrometer for use in vivo and in studies of aqueous biological samples. Rev. Sci. Instrum. 2005, 76, 013107. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
d’Hose, D.; Mathieu, B.; Mignion, L.; Hardy, M.; Ouari, O.; Jordan, B.F.; Sonveaux, P.; Gallez, B. EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells. Molecules 2022, 27, 5872. https://doi.org/10.3390/molecules27185872
d’Hose D, Mathieu B, Mignion L, Hardy M, Ouari O, Jordan BF, Sonveaux P, Gallez B. EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells. Molecules. 2022; 27(18):5872. https://doi.org/10.3390/molecules27185872
Chicago/Turabian Styled’Hose, Donatienne, Barbara Mathieu, Lionel Mignion, Micael Hardy, Olivier Ouari, Bénédicte F. Jordan, Pierre Sonveaux, and Bernard Gallez. 2022. "EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells" Molecules 27, no. 18: 5872. https://doi.org/10.3390/molecules27185872